Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 4/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493586 | 0.95 | AVPR1B (0.38) | CXCR3AVPR1BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL492872 | 0.92 | AVPR1B (0.40) | AVPR1BAVPR1AF2 | |
| SCHEMBL493271 | 0.91 | CXCR3 (0.44) | CXCR3 | |
| SCHEMBL493441 | 0.89 | AVPR1A (0.40) | CXCR3AVPR1BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL493019 | 0.86 | CXCR3 (0.46) | CXCR3LMNA | |
| SCHEMBL493275 | 0.86 | AVPR1A (0.40) | CXCR3AVPR1BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL493722 | 0.86 | AVPR1B (0.37) | CXCR3AVPR1BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL493247 | 0.85 | AVPR1A (0.37) | CXCR3AVPR1BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL493250 | 0.85 | EPHX2 (0.42) | AVPR1BALDH1A1SMN1; SMN2AVPR1A | |
| SCHEMBL493574 | 0.83 | AVPR1B (0.43) | AVPR1BAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | CXCR3 4458/4885AVPR1B 780/4885ALDH1A1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.